Related Experiment Videos
Oncogenic proteins as tumor antigens
1University of Washington, Division of Oncology, Seattle 98195-6527, USA. ndisis@u.washington.edu
Abstract:
Human immune responses to oncogenic proteins have been reported and are continuing to be defined. Immunity to nonmutated overexpressed oncoproteins as well as to mutated or unique cancer-specific oncoproteins has been identified. Immune system based treatments targeting oncogenic proteins have shown therapeutic efficacy in animals models and are currently being translated into human clinical trials.
Insights
The human immune system can recognize and respond to cancer-causing proteins (oncogenic proteins). Research is defining these immune responses and developing targeted immunotherapies for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Human immune responses to oncogenic proteins are increasingly recognized.
- Immunity has been identified against both overexpressed and mutated oncoproteins.
- This understanding is crucial for developing novel cancer therapies.
Purpose of the Study:
- To summarize the current understanding of human immune responses to oncogenic proteins.
- To highlight the identification of immunity against various types of oncoproteins.
- To underscore the translational potential of these findings in cancer treatment.
Main Methods:
- Literature review and synthesis of existing research on immune responses to oncogenic proteins.
- Analysis of studies identifying immune recognition of both mutated and non-mutated oncoproteins.
- Examination of preclinical and clinical data on immunotherapy targeting oncoproteins.
Main Results:
- Human immune responses targeting oncogenic proteins have been identified.
- Immunity is directed against a spectrum of oncoproteins, including overexpressed and mutated forms.
- Immune-based treatments targeting oncogenic proteins demonstrate efficacy in preclinical models.
Conclusions:
- The human immune system actively targets oncogenic proteins.
- Targeting these proteins with immunotherapies holds significant therapeutic promise.
- Ongoing clinical trials are evaluating the efficacy of these immune-based treatments in cancer patients.